PROHIBITION ON MESSAGING This bill enacts the "Restore Trust in Public Health Messaging Act," which prohibits the department of health, commissioner of health, an employee or agent of the department, an employee or agent of a local health department, and the state executive branch from directly or indirectly promoting, distributing, or endorsing information regarding an FDA-regulated product in a manner that conflicts with or does not accurately reflect the FDA-approved or FDA-authorized label for such product. This prohibition includes the following:  The use of any state grants or other funds, federal grants or funds distributed by this state, or other forms of inducements that may lead to the dissemination of such information.  Information concerning general categories or types of FDA-regulated products where no specific product is referenced. Information that references a general category or type must (i) be universally true for all products within the general category or type under current FDA regulations or (ii) provide qualifications or disclaimers that highlight the exceptions or limitations based on individual product labels. If the commissioner, an employee or agent of the department, an employee or agent of a local health department, or the state executive branch refers a healthcare provider or the general public to information about FDA-regulated products from sources not covered by this bill, then this bill requires the referral to include a warning that the entity for which the employee or agent is providing such information is not regulated by this bill. This bill provides that the provisions above do not prohibit the commissioner, the state executive branch, or another person subject to this bill from publicly expressing criticism of or disagreement with product authorization, approval, or labeling decisions by the FDA. This bill requires the commissioner and the state executive branch to do all of the following:  No later than July 1, 2025, establish an internal review process to ensure compliance with FDA labeling standards in all communications, educational materials, and public health campaign.  On or before January 15 of each year, submit an annual report to the comptroller of the treasury, the clerk of the senate, the clerk of the house of representatives, and the legislative librarian that details the efforts of the commissioner and the state executive branch to comply with this bill. The report must include, but is not limited to, a description of any violations and corrective actions taken to address such violations. This bill authorizes an individual to report a violation or suspected violation of this bill to the comptroller of the treasury. The comptroller of the treasury must do all of the following:  On or before July 1, 2025, establish a process by which individuals may submit information concerning violations or suspected violations of this bill.  Investigate complaints concerning alleged or suspected violations of this bill and complaints of retaliation against an individual who reported an alleged or suspected violation.  Upon finding that a violation occurred, notify in writing the violator and the director or chief executive of the entity for which the violator is an employee or agent.  Assess penalties pursuant to this bill. CORRECTIVE ACTION UPON NOTICE OF VIOLATION Within 10 days of receiving a notice from the comptroller of the treasury that an entity or an employee or agent of an entity has violated this bill, this bill requires the director or chief executive of such entity to immediately cease the dissemination of any information deemed to be in violation of this bill and issue a correction notice that (i) clearly states the nature of the violation; (ii) explains how the entity or employee or agent is correcting the violation; and (iii) is disseminated in the same manner, to the same extent, and to the same recipients as the original information found to violate this bill. REMOVAL OF NONCONFORMING MATERIALS No later than July 1, 2025, this bill requires the department, the commissioner, each local health department, the state executive branch, and each recipient of a federal grant, state grant, or other funds or inducements distributed by this state to begin to remove from public distribution all existing informational materials, whether in printed or electronic format, that are not in compliance with this bill. The removal of such materials must be completed on or before January 15, 2026. PENALTIES This bill provides that an employee or agent of the department, a local health department, or the state executive branch who violates this bill is subject to disciplinary action, which may include termination of employment or agency agreement. A violation by an entity that receives state grants or funds, federal grants or funds distributed by this state, or other forms of financial inducement:  Is subject to a civil penalty not to exceed three times the amount of state resources misused in the commission of the violation, or $50,000, whichever is greater.  Is ineligible to receive grants, funds, or other inducements for a period of one to 10 years, to be determined by the comptroller of the treasury, based on the severity of the violation. ON MARCH 13, 2025, THE SENATE ADOPTED AMENDMENTS #1 AND #2 AND RESET SENATE BILL 1031, AS AMENDED. AMENDMENT #1 makes the following revisions:  Defines "emergency use authorized product," as used in the bill, as a medical product that the federal food and drug administration has authorized for use during a public health emergency under the "Federal Food, Drug, and Cosmetic Act."  Defines "labeling," as used in the bill, as the FDA-approved product information and includes prescribing information, carton and container labeling, medication guides, patient package inserts, and instructions for use.  Defines "mask," as used in the bill, as a face covering, such as a surgical mask, medical-grade N95, or cloth facial covering worn for medical purposes.  Defines "vaccine," as used in the bill, as a substance intended for use in humans to stimulate the body's immune response against an infectious disease or pathogen, including products intended to provide passive immunity, such as monoclonal antibodies.  Revises the prohibition on the department of health, commissioner of health, an employee or agent of the department, an employee or agent of a local health department, and the state executive branch from directly or indirectly promoting, distributing, or endorsing information regarding an FDA-regulated product in a manner that conflicts with or does not accurately reflect the FDA-approved or FDA-authorized label for such product to, instead, prohibit such persons and entities from directly or indirectly promoting, distributing, or endorsing information regarding an FDA-regulated vaccine, mask, or emergency use authorized product that (i) conflicts with or does not accurately reflect the FDA-approved or FDA-authorized labeling for such vaccine, mask, or emergency use authorized product; or (ii) implies that safety or effectiveness has been established for coadministration of the vaccine, mask, or emergency use authorized product when adequately powered and well-controlled clinical trials needed to substantiate such representations have not been completed.  Changes references from "products" to "vaccines, masks, or emergency use authorized products" throughout the bill.  Requires the annual report to be submitted to the attorney general instead of the comptroller of the treasury.  Requires the attorney general, instead of the comptroller of the treasury, to (i) establish a process by which information concerning violations and suspected violations may be submitted (ii) investigate complaints and assess penalties, and (iii) otherwise enforce the bill. AMENDMENT #2 makes the following revisions:  Authorizes, instead of requires, the attorney general to (i) establish a process by which individuals may submit information concerning violations or suspected violations and (ii) investigate complaints and assess penalties.  Authorizes, instead of requires, an entity violating the bill to be subject to a civil penalty and be ineligible to receive grants, funds, or other inducements for a period of one-10 years, to be determined by the attorney general, based on the severity of the violation.  Authorizes, instead of requires, the director or chief executive, within 10 days of receiving a notice from the attorney general that their entity or an employee or agent of their entity has violated the bill, to (i) immediately cease the dissemination of any information deemed to be in violation of the bill and (ii) issue a correction notice. ON MARCH 17, 2025, THE HOUSE ADOPTED AMENDMENT #1 AND PASSED HOUSE BILL 1157, AS AMENDED. AMENDMENT #1 incorporates the changes described in the summaries for Senate Amendments # 1 and #2.